More from the Author

• Book | 2019

  Patient Capital: The Challenges and Promises of Long-Term Investing

  Victoria Ivashina and Josh Lerner

  There has never been a greater need for long-term investments. And it is increasingly unlikely that the public sector will be willing or able to fill the gap. Those best positioned to address the long-run needs are likely to be the pools of capital in the hands of pensions, insurers, sovereign wealth funds, endowments, and families. In addition to their long time frames, these institutions command enormous sums. Yet, in many cases, despite the abundance of capital and substantial need for returns, long-term investments have been problematic at best. Building on recent academic research, our own work, and many discussions with practitioners, this book outlines the key challenges facing long-term investments and suggests ways to address them. Over the past several decades, “private equity” has been the primary way in which longer-term illiquid investments have been made. In dissecting the motivations and actions of the key actors in the world of long-run investing, we have taken a careful look at traditional fund models, but we also analyzed other ways to pursue concentrated and long-term investments.

  Keywords: long-term investing; large investors; Capital; Investment; Strategic Planning; Problems and Challenges; Opportunities; Society;

  Citation:

  Ivashina, Victoria, and Josh Lerner. Patient Capital: The Challenges and Promises of Long-Term Investing. First ed. Princeton, NJ: Princeton University Press, 2019.  View Details

  CiteView DetailsFind at HarvardPurchase

  Related

• Case | HBS Case Collection | October 2012 (Revised April 2019)

  Kleiner-Perkins and Genentech: When Venture Capital Met Science

  Felda Hardymon and Tom Nicholas

  Genentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into viable therapeutic products with mass market appeal, something that most scientists agreed was at least a decade away. The founders, Herbert Boyer and Robert Swanson had limited financial resources, so they turned to Tom Perkins, the co-founder of Kleiner-Perkins, for venture funding. Genentech developed through an effective union between scientific and venture investment mindsets. In 1980 an IPO valued Genentech at $300 million. In 2009 it was fully acquired by the Swiss-based healthcare company, Roche, for $47 billion. Roche had held a majority stake in the company since 1990.

  Keywords: innovation ＆ entrepreneurship; Venture Capital; Innovation and Invention; Entrepreneurship; Technology; Science; Biotechnology Industry; United States;

  Citation:

  Hardymon, Felda, and Tom Nicholas. "Kleiner-Perkins and Genentech: When Venture Capital Met Science." Harvard Business School Case 813-102, October 2012. (Revised April 2019.)  View Details

  CiteView DetailsEducatorsPurchase

  Related

• Article | Review of Financial Studies | April 2019

  Private Equity and Financial Fragility during the Crisis

  Shai Bernstein, Josh Lerner and Filippo Mezzanotti

  Do private equity firms contribute to financial fragility during economic crises? We find that during the 2008 financial crisis, PE-backed companies increased investments relative to their peers, while also experiencing greater equity and debt inflows. The effects are stronger among financially constrained companies and those whose private equity investors had more resources at the onset of the crisis. PE-backed companies consequentially experienced higher asset growth and increased market share during the crisis.

  Keywords: Private Equity; Financial Crisis; Performance; Financial Condition;

  Citation:

  Bernstein, Shai, Josh Lerner, and Filippo Mezzanotti. "Private Equity and Financial Fragility during the Crisis." Review of Financial Studies 32, no. 4 (April 2019): 1309–1373. (Earlier version distributed as National Bureau of Economic Research Working Paper No. 23626 and Harvard Business School Working Paper No. 18-005.)  View Details

  CiteView DetailsFind at Harvard

  Related